Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lipid A is a structurally conserved glycolipid comprising a β(1→6)-linked disaccharide of glucosamine, phosphorylated and acylated with multiple (usually six) fatty acids and phosphate groups[2][4][7]. It anchors lipopolysaccharide in the bacterial outer membrane and is responsible for most of LPS's toxic effects, triggering innate immune responses via TLR4 and related receptors[1][2][3]. Despite structural variability among bacteria, Lipid A universally contributes to membrane stability and pathogenesis, and has been extensively targeted for antibiotic and immunological intervention[3][5][8]. Modifying its acylation or phosphorylation state profoundly affects its immune activity and potential therapeutic use[3][7].
Neutralization or antagonism of TLR4 activation (e.g., Eritoran); Disruption of outer membrane integrity, leading to bacterial death (e.g., polymyxins); Inhibition of biosynthetic enzymes (e.g., LpxC inhibitors); Immunomodulation as vaccine adjuvant (e.g., monophosphoryl lipid A)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lipid A moiety of lipopolysaccharide (Lipid A).